Using metalloproteins to create new drugs more efficiently
Official title: Metalloprotein catalysts for asymmetric synthesis
Funded at University of Texas Dallas · NIH-10810651 · Data updated 2026-11-12
This study is working on creating special catalysts that help make medicines more efficiently and accurately, which could lead to better and safer drugs for patients in the future.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Dallas NIH-funded |
| Lab location | 1 site (Richardson, United States) |
| Project start | September 1, 2023 |
| Project end | March 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $389,367 |
| NIH project number | 5R01GM098628-14 |
| Project ID | NIH-10810651 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for benefiting from this research include individuals who require new or improved medications for their health conditions.
✕Less likely to help
Patients who are not seeking new treatments or who do not require medications may not benefit from this research.
What this research studies
This research focuses on developing metalloprotein catalysts that can enhance the synthesis of pharmaceuticals by improving the selectivity and efficiency of chemical reactions. By leveraging the unique properties of enzymes, particularly myoglobin, the project aims to create new methods for forming complex organic molecules that are essential for drug development. The approach involves exploring new chemical transformations that can lead to the production of optically active compounds, which are crucial for effective medications. Patients may benefit indirectly as these advancements could lead to more effective and safer drugs.
Why it matters
Potential benefit: If successful, this research could lead to the development of more efficient and targeted drugs, improving treatment options for various medical conditions.
How similar studies have gone: Other research has shown promise in using enzyme-based catalysts for drug synthesis, indicating that this approach has potential for success.
Where this research is happening
-
University of Texas Dallas
Richardson, United States Active
Researchers
- Principal investigator: Fasan, Rudi — University of Texas Dallas
- Study coordinator: Fasan, Rudi
Related research
Other NIH-funded projects on the same topics.
-
Profilin as a Target to Normalize Tumor Vessels in Kidney Cancer
A new approach aims to curb blood vessel growth in a common kidney cancer by targeting a protein called Profilin 1 to improve how blood vessels form in tumors.
-
Ultrafast debinding for chairside 3D-printed zirconia dental restorations
A new ultrafast debinding method aims to dramatically shorten how quickly chairside 3D-printed zirconia dental crowns can be made.
-
Adolescents learning about themselves through friends and how it links to mood
A study with teens will test how feedback from close friends and strangers shapes their self-views and mood, using brain and behavior measurements.
-
Bilingual children with developmental language disorder: how two languages shape brain development
A study with bilingual kids who have developmental language disorder to see how knowing two languages affects their brain and language skills.
-
BET inhibitors as a potential therapy for solitary fibrous tumor (SFT)
Aimed at adults with solitary fibrous tumor, this grant explores BET inhibitors to block tumor-driving gene activity.
-
Estrogen, puberty, and early signs of psychosis in teens
This grant looks at how rising estrogen during puberty in girls may influence early brain changes and psychotic-like experiences as kids become teens.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.